A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Recruiting

Phase 2

RitlecitinibA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Sponsor:

Pfizer

Code:

NCT07219615

Conditions

Chronic Spontaneous Urticaria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ritlecitinib 50 mg

Ritlecitinib 100 mg

Placebo - 50 mg

Placebo - 100 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-09. This information was provided to ClinicalTrials.gov by Pfizer on 2026-04-13.